De Placido S, et al. - The schedule and type of aromatase inhibitors used as adjuvant treatment for hormone receptor-positive early breast cancer were determined. Patients assigned to oral anastrozole, exemestane, or letrozole tablets upfront for 5 years (upfront strategy) or oral tamoxifen for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy) were compared. No differences in efficacy were noted in treating patients for 5 years with aromatase inhibitors compared with the switch strategy. None of the three aromatase inhibitors was superior to the others. When deciding the optimal treatment approach in this setting, considering patient preference, tolerability, and financial constraints is recommended.